Status:
ACTIVE_NOT_RECRUITING
Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
Lead Sponsor:
University of California, San Diego
Conditions:
Anorexia Nervosa
Eligibility:
FEMALE
18-40 years
Phase:
EARLY_PHASE1
Brief Summary
No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established. The current study is an important first st...
Eligibility Criteria
Inclusion
- Must currently meet DSM-5 criteria for AN-R and AN Spectrum Disorders (i.e., Atypical AN) based on the Structured Clinical Interview for the DSM-5 (SCID-5-RV)
- Have a duration of illness ≥ 6 months
- Be medically stable as assessed by a comprehensive medical and behavioral evaluation conducted by a study physician
Exclusion
- Psychotic illness/other mental illness requiring inpatient hospitalization
- Current dependence on drugs or alcohol
- Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight or liver disease which may affect pharmacokinetics of the study drug
- Use of other psychoactive medications
- Significant changes in medication in past month
- Expression of acute suicidality
- Previous hypersensitivity reaction to Epidiolex or any of its constituents
Key Trial Info
Start Date :
January 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04878627
Start Date
January 20 2022
End Date
June 1 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Diego
San Diego, California, United States, 92121